v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (4,046,804) $ (2,917,280)
Adjustments to reconcile net loss to net cash used in operating activities:    
Shares issued for services 304,800 138,979
Stock-based compensation 137,544 527,625
Change in fair value of warrant liability (related party) 172,715
Loss on sale of assets 163
Change in fair value of investment (325,000) (175,000)
Non-cash expense of IPR&D 1,559
Amortization of website costs 5,198 5,174
Changes in assets and liabilities:    
Prepaid expenses and other current assets (403,553) (8,784)
Other assets (1,160) (60,089)
Accounts payable and accrued expenses (81,637) 1,032,045
Foreign currency remeasurement 84,115
Net cash used in operating activities (4,324,775) (1,284,615)
Cash flows from investing activities:    
Proceeds from sale of plant, property, and equipment 7,597
Purchase of plant, property, and equipment (17,755)
Cash paid for website costs (2,374)
Cash acquired in business combinations 150,186
Net cash (used in) provided by investing activities (10,158) 147,812
Cash flows from financing activities:    
Cash paid for stock issuance costs in business combinations (2,880)
Repurchase of common stock (78,394)
Proceeds from issuance of common stock 4,353,842
Proceeds from issuance of note payable 60,000
Proceeds from Orocidin issuance of common stock in capital raise 193,330
Proceeds from exercise of warrants 889,477
Net cash provided by financing activities 4,335,448 1,079,927
Net change in cash 515 (56,876)
Effect of exchange rate on cash 449 26,857
Cash at beginning of period 19,914 49,933
Cash at end of period 20,878 19,914
Supplemental disclosure of cash flow information:    
Income taxes paid
Interest paid
Supplemental disclosures of non-cash information:    
NoviThera equity issued for intellectual property 1,568
Common Stock issued for the acquisition of Bio-Convert 39,000,000
Common Stock issued for the acquisition of Orocidin 19,000,000
Cancellation of liability-classified warrants – related party 167,000
Forgiveness of debt - related party $ 13,886